Pages
Products
Human ENTPD1 Stable Cell Line-HEK293T

Human ENTPD1 Stable Cell Line-HEK293T

Cat.No. :  CSC-RO1051 Host Cell:  HEK293T

Inquire for Price

Cell Line Information

Cell Culture Information

Safety and Packaging

Cat. No. CSC-RO1051
Description HEK293-ENTPD1 cell line is engineered to stably overexpress human ENTPD1.
Gene ENTPD1
Gene Species Homo sapiens (Human)
Host Cell HEK293T
Host Cell Species Homo sapiens (Human)
Stability Validated for at least 10 passages
Application

1. Studying the interactions between immune cells and cancer cells

2. Studying the mechanisms of resistance to immune checkpoint blockade

3. High-throughput screening

4. Drug target validation

Quality Control Negative for bacteria, yeast, fungi and mycoplasma.
Shipping Dry ice
Storage Liquid nitrogen
Revival Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media.
Growth Properties Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Split at 80-90% confluence, approximately 1:3-1:6.
Mycoplasma Negative
Format One frozen vial containing millions of cells
Storage Liquid nitrogen
Safety Considerations

The following safety precautions should be observed.

1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum.

2. No eating, drinking or smoking while handling the stable line.

3. Wash hands after handling the stable line and before leaving the lab.

4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells.

5. All waste should be considered hazardous.

6. Dispose of all liquid waste after each experiment and treat with bleach.

Ship Dry ice
Quick Inquiry

Publications

Q & A

Customer Reviews

Customer Q&As
Are there any known ethical considerations or regulatory requirements when using the Human ENTPD1 Stable Cell Line-HEK293 for research involving human subjects or clinical applications?

A: When using the Human ENTPD1 Stable Cell Line-HEK293 in research involving human subjects or clinical applications, researchers must adhere to ethical guidelines, obtain appropriate informed consent when working with patient-derived samples, and ensure compliance with institutional review board (IRB) or ethics committee requirements. Additionally, ethical considerations related to genetic manipulation and potential therapeutic applications should be carefully evaluated.

What is the specific origin of the Human ENTPD1 Stable Cell Line-HEK293, and how was it established?

A: The Human ENTPD1 Stable Cell Line-HEK293 originates from human embryonic kidney 293 (HEK293) cells that were transfected with a stable expression construct containing the human ENTPD1 (Ectonucleoside triphosphate diphosphohydrolase 1) gene. This gene encodes for CD39, an enzyme involved in purinergic signaling and immune responses. The cell line was established through a transfection and selection process to create stable cell populations expressing human ENTPD1.

Can you provide insights into the mechanisms by which CD39 (ENTPD1) regulates purinergic signaling in the Human ENTPD1 Stable Cell Line-HEK293?

A: CD39 (ENTPD1) plays a critical role in purinergic signaling by hydrolyzing extracellular ATP and ADP into AMP. This enzymatic activity leads to the attenuation of purinergic receptor activation, specifically P2X and P2Y receptors. In the Human ENTPD1 Stable Cell Line-HEK293, CD39 expression can be studied to understand its impact on purinergic signaling and immune cell activation.

Are there any known challenges or limitations associated with working with the Human ENTPD1 Stable Cell Line-HEK293 that researchers should be aware of?

A: One potential challenge is that the Human ENTPD1 Stable Cell Line-HEK293 represents a simplified model of purinergic signaling, and its behavior may not fully mimic the complexity of in vivo immune responses. Additionally, researchers should ensure that the expression and function of CD39 (ENTPD1) are validated and consistent for reliable experimental results.

Are there any known interactions between CD39 (ENTPD1) and other cell surface receptors or molecules that may have implications in immunotherapy or drug development?

A: CD39 (ENTPD1) is known to interact with other molecules involved in the immune system, such as CD73 (another ectonucleotidase) and various purinergic receptors. These interactions can modulate the effects of adenosine, which has immunosuppressive properties. Targeting CD39 in immunotherapy has been explored to enhance anti-tumor immune responses, making it an attractive target for drug development.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction